Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies

Si et al. identify that HPK1 promotes T cell dysfunction via NFκB-Blimp1 activation and demonstrate that it is an attractive druggable target to improve immunotherapies by generating MAP4K1KO CAR-T cells, a small-molecule HPK1 inhibitor, and a proteolysis targeting chimera (PROTAC).

from Cancer Cell https://ift.tt/2QxfiwV